Results 111 to 120 of about 254,454 (341)

The cost and cost-effectiveness of alternative strategies to expand treatment to HIV-positive South Africans: scale economies and outreach costs [PDF]

open access: yes, 2015
This repository item contains a single issue of the Health and Development Discussion Papers, an informal working paper series that began publishing in 2002 by the Boston University Center for Global Health and Development.
Bershteyn, Anna   +3 more
core   +2 more sources

Physiotherapy in multiple sclerosis

open access: yesStudia Medyczne, 2015
Introduction: Multiple sclerosis (MS) is a chronic, progressive, demyelinating disease of the central nervous system. 2.5 million people are affected by MS worldwide; in Poland, the number of patients is approximately 40,000.
Anna Łuszczyńska   +1 more
doaj   +1 more source

Development of a Personalized Visualization and Analysis Tool to Improve Clinical Care in Complex Multisystem Diseases With Application to Scleroderma

open access: yesArthritis Care &Research, EarlyView.
Objective In complex diseases, it is challenging to assess a patient's disease state, trajectory, treatment exposures, and risk of multiple outcomes simultaneously, efficiently, and at the point of care. Methods We developed an interactive patient‐level data visualization and analysis tool (VAT) that automates illustration of the trajectory of a ...
Ji Soo Kim   +18 more
wiley   +1 more source

Smoking cessation and the reduction of disability progression in Multiple Sclerosis: a cohort study [PDF]

open access: yes, 2017
Background: Smoking is associated with a more severe disease course in people with multiple sclerosis (MS). The magnitude of effect of smoking cessation on MS progression is unknown.
Constantinescu, Cris S.   +3 more
core   +2 more sources

Economic Burden of Rheumatoid Arthritis in Low‐ and Middle‐Income Countries: Systematic Review and Meta‐Analysis

open access: yesArthritis Care &Research, EarlyView.
Objective The aim of this systematic review was to synthesize the economic impact of rheumatoid arthritis (RA) on households, health systems, and society in low‐ and middle‐income countries (LMICs). Methods Electronic databases such as PubMed, Web of Science, and CINAHL were searched using keywords related to RA and cost of illness.
Tadesse Gebrye   +6 more
wiley   +1 more source

Oral contraceptives combined with interferon β in multiple sclerosis [PDF]

open access: yes, 2015
Objective: To test the effect of oral contraceptives (OCs) in combination with interferon b (IFN-b) on disease activity in patients with relapsing-remitting multiple sclerosis (RRMS).
Barletta, Valeria T.   +10 more
core   +3 more sources

1 Patient-determined disease steps is not equivalent to the expanded disability status scale in mild to moderate multiple sclerosis [PDF]

open access: gold, 2023
Yi Chao Foong   +14 more
openalex   +1 more source

Identifying High‐Impact Solutions to Address Racial and Ethnic Health Disparities in Lupus: A Consensus‐Based Approach

open access: yesArthritis Care &Research, EarlyView.
Objective We conducted formative research aimed at identifying solutions that address inequitable health outcomes in lupus due to adverse social determinants of health (SDoH). Methods We conducted a search for keywords, which provided insights into potential solutions and initiatives underway. An advisory panel of lupus experts iteratively reviewed the
Joy Buie   +11 more
wiley   +1 more source

Progressive decline of decision-making performances during multiple sclerosis [PDF]

open access: yes, 2017
The purpose of this study was to evaluate longitudinally, using the Iowa Gambling Task (IGT), the dynamics of decision-making capacity at a two-year interval (median: 2.1 years) in a group of patients with multiple sclerosis (MS) (n = 70) and minor ...
ANNONI, JEAN-MARIE   +6 more
core  

Rethinking Strategies for a Pharmaceutical Approach to Pain Related to Connective Tissue–Related Raynaud Phenomenon in the United States

open access: yesArthritis Care &Research, EarlyView.
Objective There are no US Food and Drug Administration–approved therapies for Raynaud phenomenon (RP) in the United States. Clinical trials have been challenged by study design. Important advances in RP patient‐reported outcome measures and mechanistic quantification allow RP‐related pain characterization.
Tracy M. Frech   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy